Amended and Restated Investors' Rights Agreement



 Exhibit 10.5 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 
 THIS AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of the 19th day of July, 2011, by and among Proto Labs, Inc., a Minnesota corporation (the “Company”), and each of the investors listed on
Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” and amends and restates that certain Investors’ Rights Agreement (the “Predecessor Agreement”), dated as of
August 1, 2008, by and among the Company, North Bridge Growth Equity I, L.P., a Delaware limited partnership (“North Bridge”) and Protomold Investment Company, LLC, a Minnesota limited liability company
(“PIC”). 
 RECITALS 
 A. The Company and PIC terminated that certain Stock Purchase Agreement, dated June 17, 2005, as amended (the “PIC Agreement”) and replaced it with the Predecessor Agreement.

 B. The Company and North Bridge are parties to the Series A Preferred Stock Purchase Agreement, dated as of August 1,
2008 (the “Purchase Agreement”). 
 C. In order to induce the Company to enter into the Purchase Agreement and
to induce North Bridge, an Investor under the Predecessor Agreement, to invest funds in the Company pursuant to the Purchase Agreement, North Bridge and the Company executed the Predecessor Agreement. 

D. The Company, North Bridge and PIC, together with the other Investors listed on Schedule A, desire to amend and restate the
Predecessor Agreement to reflect certain agreements reached by such parties, including the granting of piggyback registration rights as described below to each of the Lawrence Lukis, Bradley A. Cleveland, individually and as trustee of the Bradley
A. Cleveland Declaration of Trust dated October 10, 2008, Donald Krantz and Mark Kubicek, and Patricia M. Cleveland and Cornerstone Private Asset Trust Company, LLC, as Co-Trustees of the KEC 2011 Irrevocable Gift Trust and the JMC 2011
Irrevocable Gift Trust (collectively the “Management Investors” and each a “Management Investor”). 
 NOW, THEREFORE, the parties agree as follows: 
  

	 	1.	Definitions. For purposes of this Agreement: 

 1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person,
including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same
management company with, such Person. 
 1.2 “Common Stock” means shares of the Company’s common stock,
par value $.001 per share. 

  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 1	  









 1.3 “Damages” means any loss, damage, or liability (joint or several) to
which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, or liability (or any action in respect thereof) arises out of or is based upon (i) any untrue
statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an
omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents
or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.4 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each
case, directly or indirectly), Common Stock, including options and warrants. 
 1.5 “Exchange Act” means the
Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.6
“Excluded Registration” means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration
relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities;
or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 
 1.7 “Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by
the SEC. 
 1.8 “Form S-3” means such form under the Securities Act as in effect on the date hereof or any
registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

1.9 “GAAP” means generally accepted accounting principles in the United States. 

1.10 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.11 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent,
spouse, domestic partner, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of a natural person referred to herein. 

  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 2	  









 1.12 “Initiating Holders” means, collectively, Holders who properly
initiate a registration request under this Agreement. 
 1.13 “IPO” means the Company’s first
firm-commitment underwritten public offering of its Common Stock pursuant to an effective registration statement under the Securities Act. 
 1.14 “Major Holder” means North Bridge or PIC, so long as each, respectively, remains a Holder. 
 1.15 “Major Investor” means any of North Bridge or PIC, individually or together with such Investor’s Affiliates, so long as such Investor holds at least 75,000 shares of Registrable
Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof). 
 1.16 “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity
securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 
 1.17 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity. 

1.18 “Qualified IPO” means the Company’s first firm-commitment underwritten public offering of its Common Stock
pursuant to an effective registration statement under the Securities Act (provided that if such a public offering is consummated before August 1, 2012, the offering price must be at least $244.12 per share (subject to appropriate adjustment in
the event of any stock dividend, stock split, combination or other similar recapitalization), resulting in at least $40,000,000 of aggregate gross proceeds to the Company). 
 1.19 “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Series A Preferred Stock, (ii) the Common Stock issued to PIC, (iii) the
Common Stock issued to any Management Investor, and (iv) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in
exchange for or in replacement of, the shares referenced in clauses (i) and (iii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are
not assigned pursuant to Section 5.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Section 2.14 of this Agreement. 

1.20 “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of
outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

1.21 “Restricted Securities” means the securities of the Company required to bear the legend set forth in
Section 2.12(b) hereof. 

  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 3	  









 1.22 “SEC” means the Securities and Exchange Commission. 

1.23 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.24 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.25 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. 
 1.26 “Selling Expenses” means all underwriting discounts, selling commissions, and stock
transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in
Section 2.6. 
 1.27 “Series A Director” means any director of the Company that the holders of
record of the Series A Preferred Stock are entitled to elect pursuant to the Company’s Amended and Restated Articles of Incorporation. 
 1.28 “Series A Holder” means North Bridge Growth Equity I, L.P. 

1.29 “Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $.001 per share.

  

	 	2.	Registration Rights. The Company covenants and agrees as follows: 

 2.1 Demand Registration. 
 (a) Form S-1 Demand. If at any time
following 180 days after the effective date of the registration statement for an IPO, the Company receives a request from Major Holders of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with
respect to outstanding Registrable Securities having an anticipated aggregate offering price, net of Selling Expenses, of at least $5,000,000, then the Company shall (i) within ten days after the date such request is given, give notice thereof
(the “Demand Notice”) to all Major Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within 60 days after the date such request is given by the Initiating Holders, file a Form S-1
registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Major
Holders, as specified by notice given by each such Major Holder to the Company within 20 days of the date the Demand Notice is given, and in each case, subject to the limitations of Section 2.1(c) and Section 2.3. 

(b) Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a
request from Major Holders of Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Major Holders having an anticipated aggregate offering price,
net of Selling Expenses, of at least $3,000,000, then the Company shall 

  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 4	  









 
(i) within 10 days after the date such request is given, give a Demand Notice to all Major Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within
45 days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Major Holders, as
specified by notice given by each such Major Holder to the Company within 20 days of the date the Demand Notice is given, and in each case, subject to the limitations of Section 2.1(c) and Section 2.3. 

(c) Notwithstanding the foregoing obligations, if the Company furnishes to Major Holders requesting a registration pursuant to this
Section 2.1 a certificate signed by the Company’s Chief Executive Officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially detrimental to the Company and its shareholders for
such registration statement to be filed and it is therefore necessary to defer the filing of such registration statement, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to
filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than 105 days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any
12 month period; and provided further that the Company shall not register any securities for its own account or that of any other shareholder during such 105-day period other than an Excluded Registration. 

(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
Section 2.1(a) (i) during the period that is 60 days before the Company’s good faith estimate of the date of filing of, and ending on a date that is 180 days after the effective date of, a Company-initiated registration,
provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected three registrations pursuant to
Section 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b). The Company
shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(b) (i) during the period that is 30 days before the Company’s good faith estimate of the date of filing of, and ending
on a date that is 90 days after the effective date of, a Company-initiated registration, provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or
(ii) if the Company has effected two registrations pursuant to Section 2.1(b) within the 12 month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of
this Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses
therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Section 2.1(d).
 
 2.2 Company Registration. If the Company proposes to register (including, for this purpose, a registration
effected by the Company for any shareholder of the Company) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such


  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 5	  









 
time, promptly give each Holder notice of such registration. Upon the request of each Holder given within 20 days after such notice is given by the Company, the Company shall, subject to the
provisions of Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration
initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such
withdrawn registration shall be borne by the Company in accordance with Section 2.6. 
 2.3 Underwriting
Requirements. 
 (a) If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable
Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such information in the Demand Notice. The
underwriter(s) will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration
shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities
through such underwriting shall (together with the Company as provided in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision
of this Section 2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all
Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the
Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the
number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. 

(b) In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to
Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its
underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by
shareholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company
shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the
underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then, the Registrable Securities that are included in such offering shall be allocated among the


  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 6	  









 
selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all
such selling Holders. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely
excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below 30% of the total number of securities included in such offering, unless such offering is an IPO, in which case the selling
Holders may be excluded further if the underwriters make the determination described above and no other shareholder’s securities are included in such offering. For purposes of the provision in this Section 2.3(b) concerning
apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, shareholders, and Affiliates of such Holder, or the estates and Immediate Family
Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such
“selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 

(c) For purposes of Section 2.1, a registration shall not be counted as “effected” if, as a result of an exercise
of the underwriter’s cutback provisions in Section 2.3(a), fewer than 50% of the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually included. 

2.4 Obligations of the Company. Whenever required under this Section 2 to effect the registration of any Registrable
Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) prepare and file with the SEC a registration
statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered
thereunder, keep such registration statement effective for a period of up to 120 days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such 120 day period
shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the
case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such 120 day period shall be extended for up to one year, if necessary,
to keep the registration statement effective until all such Registrable Securities are sold; 
 (b) prepare and file with the
SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities
covered by such registration statement; 
 (c) furnish to the selling Holders such numbers of copies of a prospectus, including
a preliminary prospectus, as required by the Securities Act, and such other 

  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 7	  









 
documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such
other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent to service of process in
any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 
 (e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering;

 (f) use its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement
to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP
number for all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h)
promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or
selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information
reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in
connection therewith; 
 (i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when
such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of
such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 8	  









 2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in
connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the
reasonable fees and disbursements, not to exceed $50,000 of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to
pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which
case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their
right to one registration pursuant to Section 2.1(a) or Section 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the
condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay
any of such expenses and shall not forfeit their right to one registration pursuant to Section 2.1(a) or Section 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this
Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 
 2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any
controversy that might arise with respect to the interpretation or implementation of this Section 2. 
 2.8
Indemnification. If any Registrable Securities are included in a registration statement under this Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, and shareholders of each such Holder; legal counsel
and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any
Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from
which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such
settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance
upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. 

  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 9	  









 (b) To the extent permitted by law, each selling Holder, severally and not jointly, will
indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and
accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each
case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such
registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages
may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is
effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Sections 2.8(b)
and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of any action
(including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.8, give the
indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which
notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by
one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate
due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have
to any indemnified party otherwise than under this Section 2.8, except to the extent that such failure materially prejudices the indemnifying party’s ability to defend the action. 

(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either (i) any
party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section 2.8 provides for indemnification in such case, or
(ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Section 2.8, then, and in each such case, such parties will contribute to the aggregate
losses, 

  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 10	  









 
claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the
indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The
relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material
fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided,
however, that, in any such case, (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and
(y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided
further that in no event shall a Holder’s liability pursuant to this Section 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b), exceed the proceeds from the offering
received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 
 (e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public
offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 
 (f)
Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of
Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell
securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 

(a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times
after the effective date of the registration statement filed by the Company for an IPO; 
 (b) use commercially reasonable
efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent
accurate, a written statement by the Company 

  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 11	  









 
that it has complied with the reporting requirements of SEC Rule 144 (at any time after 90 days after the effective date of the registration statement filed by the Company for an IPO), the
Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company
so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any Holder of
any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after
the Company so qualifies to use such form). 
 2.10 Limitations on Subsequent Registration Rights. From and after the
date of this Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the
Company that (i) would allow such holder or prospective holder to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only
to the extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included, or (ii) would allow such holder or prospective holder to initiate a demand for registration of any
securities held by such holder or prospective holder; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Section 7.9. 

2.11 “Market Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the
managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company of shares of its Common Stock or any other equity securities under the Securities Act on a registration statement on
Form S-1 and ending on the date specified by the Company and the managing underwriter (such period not to exceed 180 days), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or
contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for
Common Stock held immediately before the effective date of the registration statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of
ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this
Section 2.11 shall apply only to an IPO, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall be applicable to the Holders only if all officers and directors of the Company are
subject to the same restrictions. The underwriters in connection with such registration are intended third-party beneficiaries of this Section 2.11 and shall have the right, power, and authority to enforce the provisions hereof as though
they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Section 2.11 or that are necessary to
give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the 

  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 12	  









 
underwriters shall apply pro rata to all Holders subject to such agreements, based on the number of shares subject to such agreements, except that, notwithstanding the foregoing, the Company and
the underwriters may, in their sole discretion, waive or terminate these restrictions with respect to up to 1,000 shares of the Common Stock. 
 2.12 Restrictions on Transfer. 
 (a) The Series A Preferred Stock and
the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the
conditions specified in this Section 2.12, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Series A
Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Section 2.12. 

(b) Each certificate or instrument representing (i) the Series A Preferred Stock, (ii) the Registrable Securities, and
(iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by
the provisions of Section 2.12(c)) be stamped or otherwise imprinted with a legend substantially in the following form: 
 THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE
SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
 THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT
BETWEEN THE COMPANY AND THE SHAREHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company
making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 

(c) The holder of each certificate representing Restricted Securities, by acceptance thereof, agrees to comply in all respects with the
provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof
shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or 

  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 13	  









 
transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be
accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed
transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not
result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the
Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the
notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144, (y) in any transaction in which such Holder transfers
Restricted Securities to an Affiliate of such Holder for no consideration, or (z) in any transaction in which an individual Holder transfers Restricted Securities to such Holder’s Immediate Family Member or trust for the benefit of an
individual Holder or one or more of such Holder’s Immediate Family Members; provided that each transferee agrees in writing to be subject to the terms of this Section 2.12. Each certificate or instrument evidencing the Restricted
Securities transferred as above provided shall bear, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Section 2.12(b), except that such certificate shall not bear such
restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act. 

2.13 [Intentionally Omitted.] 
 2.14 Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Section 2.1 or
Section 2.2 shall terminate upon the earliest to occur of: 
 (a) the closing of a Deemed Liquidation Event, as
such term is defined in the Company’s Amended and Restated Articles of Incorporation; 
 (b) the date on which all shares
of Registrable Securities held by such Holder may be sold under Rule 144 within a 90 day period for any continuous 180 day period; and 
 (c) the fifth anniversary of the date of the IPO. 
  

	 	3.	Information Rights. 

 3.1
Delivery of Financial Statements. The Company shall deliver to each Major Investor: 
 (a) as soon as practicable, but
in any event within 150 days after the end of each fiscal year of the Company (and no later than when provided to the Company’s lenders), (i) a balance sheet as of the end of such year, (ii) statements of income and of cash


  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 14	  









 
flows for such year, and a comparison between (x) the actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as included in the Budget (as
defined in Section 3.1(d)) for such year, with an explanation of any material differences between such amounts and a schedule as to the sources and applications of funds for such year, and (iii) a statement of shareholders’
equity as of the end of such year, with the financial statements audited and certified by independent public accountants selected by the Company; 
 (b) as soon as practicable, but in any event within 45 days after the end of each of the first three quarters of each fiscal year of the Company, unaudited statements of income and of cash flows for such
fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain
all notes thereto that may be required in accordance with GAAP); 
 (c) as soon as practicable, but in any event within 45 days
after the end of each of the first three quarters of each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock
outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of
shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company, and certified by
the chief financial officer or chief executive officer of the Company as being true, complete, and correct; 
 (d) as soon as
practicable, but in any event within 30 days of the end of each month, an unaudited income statement and statement of cash flows for such month, and an unaudited balance sheet as of the end of such month, all prepared in accordance with GAAP (except
that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(e) as soon as practicable, but in any event 30 days after the start of each fiscal year, a budget and business plan for that fiscal
year (collectively, the “Budget”), approved by the Board of Directors and prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other
budgets or revised budgets prepared by the Company; and 
 (f) such other information relating to the financial condition,
business, prospects, or corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Section 3.1 to provide information
(i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or (ii) the disclosure of which would
adversely affect the attorney-client privilege between the Company and its counsel. 
 If, for any period, the Company has any subsidiary whose
accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the 

  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 15	  









 
foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information set forth in this
Section 3.1 during the period starting with the date 30 days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable
to such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to
cause such registration statement to become effective. 
 3.2 Inspection. The Company shall permit each Major Investor,
at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of
the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably and in good faith
considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the
Company and its counsel. 
 3.3 Termination of Information Rights. The covenants set forth in Section 3.1 and
Section 3.2 shall terminate and be of no further force or effect (i) immediately before the consummation of a Qualified IPO or (ii) upon a Deemed Liquidation Event, whichever event occurs first. 

3.4 Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any
purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless
such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.4 by such Investor), (b) is or has been independently developed or conceived by the
Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company;
provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its
investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Section 3.4; (iii) to any existing or
prospective Affiliate, partner, member, shareholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person
to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such
required disclosure. 

  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 16	  










	 	4.	Rights to Future Stock Issuances. 

 4.1 Right of First Offer. Subject to the terms and conditions of this Section 4.1 and applicable securities laws, if the Company proposes to offer or sell any New Securities, the
Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it among itself and its Affiliates in such proportions as it deems appropriate.

 (a) The Company shall give notice (the “Offer Notice”) to each Major Investor, stating (i) its bona
fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within 20 days after the Offer Notice is given, each Major Investor may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities that equals the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or
exercise, as applicable, of the Series A Preferred Stock and any other Derivative Securities then held, by such Major Investor bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable,
of all Series A Preferred Stock and other Derivative Securities). At the expiration of such 20 day period, the Company shall promptly notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a
“Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the
Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which
is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Series A Preferred Stock and any other Derivative Securities then held, by such Fully
Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Series A Preferred Stock and any other Derivative Securities then held, by all Fully
Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Section 4.1(b) shall occur within the later of 90 days of the date that the Offer Notice is given and the date of initial sale
of New Securities pursuant to Section 4.1(c). 
 (c) If all New Securities referred to in the Offer Notice are not
elected to be purchased or acquired as provided in Section 4.1(b), the Company may, during the 90 day period following the expiration of the periods provided in Section 4.1(b), offer and sell the remaining unsubscribed
portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New
Securities within such period, or if such agreement is not consummated within the later of such 90 day period or 30 days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be
offered unless first reoffered to the Major Investors in accordance with this Section 4.1. 

  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 17	  









 (d) The right of first offer in this Section 4.1 shall not be applicable to the
following: (i) securities (including options to purchase shares of Common Stock) issued or issuable to Company management or personnel under the Company’s 2000 Stock Option Plan, as amended, and under any replacement or successor plan
approved by the Board of Directors and the Company’s shareholders; (ii) securities issued in connection with a debt financing, acquisition or strategic transaction approved by the Board of Directors; (iii) securities issued upon
conversion of any of the Series A Preferred Stock, or as a dividend or distribution on the Series A Preferred Stock; (iv) securities issued upon the conversion of any warrant, option, or other convertible security approved by the Board of
Directors and outstanding as of the date of this Agreement; (v) securities issuable upon a stock split, stock dividend, or any subdivision of shares of Common Stock; (vi) any right, option or warrant to acquire any security convertible
into the securities covered by the foregoing; and (vii) shares of Common Stock issued in an IPO. 
 (e) Notwithstanding
any provision hereof to the contrary, in lieu of complying with the provisions of this Section 4.1, the Company may elect to give notice to the Major Investors within 30 days after the issuance of New Securities. Such notice shall
describe the type, price, and terms of the New Securities. Each Major Investor shall have 20 days from the date notice is given to elect to purchase up to the number of New Securities that would, if purchased by such Major Investor, maintain such
Major Investor’s percentage-ownership position, calculated as set forth in Section 4.1(b) before giving effect to the issuance of such New Securities. The closing of such sale shall occur within 60 days of the date notice is given
to the Major Investors. 
 4.2 Termination. The covenants set forth in Section 4.1 shall terminate and be of
no further force or effect (i) immediately before the consummation of an IPO or (ii) upon a Deemed Liquidation Event, whichever event occurs first. 
  

	 	5.	Additional Covenants. 


5.1 Insurance. The Company shall use its commercially reasonable efforts to obtain, within 90 days of the date hereof, from
financially sound and reputable insurers term “key-person” insurance on Larry Lukis and Brad Cleveland, each in an amount of $2.5 million and on terms and conditions satisfactory to the Board of Directors, and will use commercially
reasonable efforts to cause such insurance policies and its existing Directors and Officers liability insurance to be maintained until such time as the Board of Directors determines that such insurance should be discontinued. The key-person policy
shall name the Company as loss payee, and neither policy shall be cancelable by the Company without prior approval by the Board of Directors. 
 5.2 Employee Agreements. The Company will use reasonable efforts to obtain from each (i) senior manager and software developer now or hereafter employed by it or by any subsidiary (or engaged
by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement and (ii) Key Employee to enter into
a non-competition and non-solicitation agreement, substantially in the form approved by the Board of Directors. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced
agreements or any restricted stock 

  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 18	  









 
agreement between the Company and any employee, without the consent of the Board of Directors. 
 5.3 Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the Board of Directors shall meet at least quarterly in accordance with an agreed-upon
schedule. The Company shall reimburse the nonemployee directors for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors. The Company
will maintain an audit and compensation committee, each of which shall consist solely of non-management directors. Each non-employee director shall be entitled in such person’s discretion to be a member of any Board committee. Any future
increase to Larry Lukis’ compensation must be approved by the Company’s compensation committee.
 5.4 Successor
Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary,
proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether
such obligations are contained in the Company’s By-laws, its Articles of Incorporation, or elsewhere, as the case may be. 

5.5 Termination of Covenants. The covenants set forth in this Section 5, except for Section 5.4, shall
terminate and be of no further force or effect (i) immediately before the consummation of the IPO or (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or
(iii) upon a Deemed Liquidation Event, whichever event occurs first. 
  

	 	6.	Put Right. 

 6.1
Put. PIC shall have the right to tender all or any portion of its Registrable Securities to the Company and the Company shall be obligated to purchase and redeem such Registrable Securities so tendered (to the extent that funds are legally
available for redemption), provided that PIC shall not tender less than 10,000 shares of Registrable Securities (subject to adjustment for stock dividends, stock combinations, reorganizations and similar events) on any one occasion upon PIC’s
exercise of its put right pursuant to Section 6.2 below. 
 6.2 Notice of Exercise. PIC may exercise its put
option under Section 6.1 at any time after August 2, 2018. Notice of exercise of the put option shall be given to the Company in writing pursuant to the notice provisions set forth in this Agreement, and shall specify the number of
shares of Registrable Securities being tendered to the Company for sale. 
 6.3 Purchase Price. The purchase price for
shares of Registrable Securities tendered to the Company pursuant to this Section 6 shall be determined as follows: upon receipt of by the Company of PIC’s notice of election to exercise the put option pursuant to
Section 6.2, PIC and an authorized representative of the Company shall meet and attempt in good faith to agree upon the purchase price applicable to the redemption of shares of Registrable Securities


  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 19	  









 
under this Section 6. If the parties fail to agree upon such purchase price within 30 days after the Company’s receipt of PIC’s notice of election to exercise its put
option, the purchase price shall be determined by an independent appraisal without discount for lack of liquidity, control or marketability. The appraised fair market value of the shares of Registrable Securities shall be determined as of the last
day of the fiscal year during which the right to put Shares becomes exercisable. The appraisal shall be prepared by a qualified appraiser selected by the Company and acceptable to PIC, with the fees and expenses of the qualified appraisal being
split equally between the Company and PIC. If PIC and the Company cannot agree upon a qualified appraiser, then each party shall select its own qualified appraiser and each appraiser shall separately determine the fair market value of the shares of
Registrable Securities. The purchase price in such case shall be the average of the two appraisals and each party shall bear the costs of their own qualified appraiser. The purchase price determined by the appraiser, or the average of the prices
determined by the two appraisers, as applicable, shall be final and binding upon PIC and the Company. 
 6.4 Payment. The
closing of the sale and redemption of shares under this Section 6 shall occur on a reasonable date, at a reasonable place and at a reasonable time to be agreed among the parties, which shall be no later than forty-five (45) days
after the Company’s receipt of PIC’s notice of election to exercise its put option or fifteen days following the determination of the purchase price, whichever is later. PIC shall be entitled to interest on the purchase price for the
shares at the prevailing prime rate published in The Wall Street Journal from the date of the Company’s receipt of PIC’s notice of election to exercise its put option. 

6.5 Inability to Redeem. If the Company’s funds legally available for redemption of capital stock are insufficient to
discharge in full the Company’s obligations to redeem shares which the Company is then obligated to redeem pursuant to this Section 6, the Company shall redeem the maximum number of shares for which it has sufficient funds. PIC
shall receive interest (“Redemption Interest”) on the aggregate purchase price of the unredeemed shares at a rate per annum equal to 2% in excess of the prevailing prime rate published in The Wall Street Journal. Such
Redemption Interest shall accrue commencing on the date the Company would have otherwise been obligated to redeem the subject shares and shall be payable quarterly in arrears. When additional funds of the Company are legally available for the
redemption of capital stock of the Company, such funds shall be immediately used (i) to redeem the balance of the shares which it has not redeemed (in the manner described in the immediately preceding sentence), and (ii) to pay the
Redemption Interest. 
 6.6 Termination. The rights and covenants set forth in this Section 6 shall terminate
and be of no further force or effect immediately before the consummation of an IPO. 
  

	 	7.	Miscellaneous. 

 7.1
Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s
Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds at least 150,000 shares of Registrable Securities (subject to
appropriate adjustment for stock splits, stock dividends, combinations, and other 

  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 20	  









 
recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the
Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including
the provisions of Section 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or shareholder of a Holder; (2) who is a
Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that
all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this
Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their
respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 
 7.2 Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Minnesota, regardless of the laws that might otherwise govern under applicable
principles of conflicts of law. The parties hereto agree that any action brought by any party under or in relation to this Agreement, including without limitation to interpret or enforce any provision of this Agreement, shall be brought subject to
the non-exclusive jurisdiction and venue of any state or federal court located in Minnesota. The parties hereby irrevocably waive, to the fullest extent permitted by applicable law, any objection which they may now or hereafter have to the laying of
venue of any such dispute brought in such court or any defense of inconvenient forum for the maintenance of such dispute. Each party agrees that a final judgment in any action or proceeding so brought shall be conclusive and may be enforced by suit
on the judgment or in any other manner provided by law or at equity. 
 7.3 Counterparts; Facsimile. This Agreement may
be executed and delivered by facsimile signature and in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

7.4 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement. 
 7.5 Notices. All notices and other communications given or
made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or: (i) personal delivery to the party to be notified, (ii) when sent, if sent by electronic mail or facsimile
during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next business day, (iii) five days after having been sent by registered or certified mail, return receipt requested,
postage prepaid, or (iv) one business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt. All communications shall
be sent to the respective parties at their address as set forth on Schedule A  

  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 21	  









 
hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number or address as
subsequently modified by written notice given in accordance with this Section 7.5. If notice is given to the Company, a copy shall also be sent to Faegre & Benson LLP, 2200 Wells Fargo Center, 90 South Seventh Street,
Minneapolis, MN 55402, Attention: Mark D. Pihlstrom, and if notice is given to the Major Holders, a copy shall also be given to Weil, Gotshal & Manges LLP, 100 Federal Street, Floor 34, Boston, MA 02110, Attention: Kevin J. Sullivan, and to
Briggs and Morgan, Professional Association, 2200 IDS Center, 80 South 8th Street, Minneapolis, MN 55402, Attention: Steve Kozachok. 
 7.6
Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written
consent of the Company and each Investor; provided that the Company may in its sole discretion waive compliance with Section 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed
assignment allegedly in violation of Section 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other
party. Notwithstanding the foregoing, neither PIC’s nor any Management Investor’s consent to any amendment or waiver shall be required if such amendment or waiver does not adversely affect PIC or such Management Investor, as applicable, in
a manner materially different than any other Investor; provided that PIC or such Management Investor, as applicable, shall be given prompt written notice of any such amendment or waiver to which PIC or such Management Investor, as applicable, did
not consent. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision.

 7.7 Severability. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or
enforceability of any other provision. 
 7.8 Aggregation of Stock. All shares of Registrable Securities held or acquired
by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

7.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of
the Company’s Series A Preferred Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of such shares of Series A Preferred Stock may become a party to this Agreement by executing and delivering an
additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional
Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 
 7.10 Entire Agreement. This Agreement (including Schedule A hereto) constitutes the full and entire understanding and agreement among the parties with respect to the


  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 22	  









 
subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties, including the Predecessor Agreement, is expressly canceled.

 7.11 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under
this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such
breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this
Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 
 [Remainder of Page
Intentionally Left Blank – Signature Pages Follow] 

  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Page 23	  









 IN WITNESS WHEREOF, the parties have executed this Investors’ Rights Agreement as of
the date first written above. 
  

					
	 COMPANY:

	
	 PROTO LABS, INC.

		
	 By:
	 	 /s/ Bradley A. Cleveland

	 Name:
	 	Bradley A. Cleveland
		
	 Title:
	 	President and Chief Executive Officer



  

			
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	Signature Page









 
			
	INVESTORS:
	
	 NORTH BRIDGE GROWTH EQUITY I, L.P.

	
	 By: North Bridge Growth Management, L.P.,

       its General Partner

	
	 By: NBGE GP, LLC, its General Partner

		
	 By:
	 	 /s/ Douglas Kingsley

	 Name:
	 	Douglas Kingsley
	 Title:
	 	Partner
	
	PROTOMOLD INVESTMENT COMPANY, LLC
		
	 By:
	 	 /s/ Brian K. Smith

	 Name:
	 	Brian K. Smith
	 Title:
	 	Chief Manager
		
	 Signature:
	 	 /s/ Lawrence Lukis

	 Name:
	 	Lawrence Lukis
		
	 Signature:
	 	 /s/ Bradley A. Cleveland

	 Name:
	 	Bradley A. Cleveland
		
	 Signature:
	 	 /s/ Bradley A. Cleveland

	 Name:
	 	Bradley A. Cleveland, as Trustee of the
		 	Bradley A. Cleveland Declaration of Trust
		 	dated October 10, 2008
		
	 Signature:
	 	 /s/ Donald Krantz

	 Name:
	 	Donald Krantz
		
	 Signature:
	 	 /s/ Mark Kubicek

	 Name:
	 	Mark Kubicek



  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Signature Page	  










			
	INVESTORS:
		
	Signature:	 	 /s/ Patricia M. Cleveland

	Name:	 	Patricia M. Cleveland, as Co-Trustee of the KEC 2011 Irrevocable Gift Trust
		
	Signature:	 	 /s/ Anne Brenner

	Name:	 	Cornerstone Private Asset Trust Company, LLC, as Co-Trustee of the KEC 2011 Irrevocable Gift Trust
		
	Signature:	 	 /s/ Patricia M. Cleveland

	Name:	 	Patricia M. Cleveland, as Co-Trustee of the JMC 2011 Irrevocable Gift Trust
		
	Signature:	 	 /s/ Anne Brenner

	Name:	 	Cornerstone Private Asset Trust Company, LLC, as Co-Trustee of the JMC 2011 Irrevocable Gift Trust



  

					
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	 	Signature Page	  









 SCHEDULE A 

INVESTORS 
  

					
	 Name and Address
	  	Number of Shares Held	 
		
	 North Bridge Growth Equity I, L.P.
	  	 	427,985	  
		
	 Protomold Investment Company, LLC
	  	 	227,832	  
		
	 Lawrence Lukis
	  	 	495,310	  
		
	 Bradley A. Cleveland
	  	 	—  	  
		
	 Bradley A. Cleveland, as Trustee of the

Bradley A. Cleveland Declaration of Trust dated October 10, 2008
	  	 	89,013	  
		
	 Donald Krantz
	  	 	—  	  
		
	 Mark Kubicek
	  	 	7,500	  
		
	 Patricia M. Cleveland and Cornerstone Private Asset Trust Company,

LLC, as Co-Trustees of the KEC 2011 Irrevocable Gift Trust

c/o Cornerstone Private Asset Trust Company, LLC
	  	 	10,000	  
		
	 Patricia M. Cleveland and Cornerstone Private Asset Trust Company,

LLC, as Co-Trustees of the JMC 2011 Irrevocable Gift Trust

c/o Cornerstone Private Asset Trust Company, LLC
	  	 	10,000	  


  

			
	 Proto Labs, Inc.: Amended and Restated Investors’ Rights Agreement
	  	Schedule A